This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Value Investors Buy Select Medical (SEM) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Select Medical (SEM) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Q2 Earnings Lag Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of -0.79% and +1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Select Medical (SEM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Select Medical Expands Presence in Tennessee With Ballad Health Deal
by Zacks Equity Research
SEM partners with Ballad Health to relocate and expand its Tri-Cities critical illness recovery hospital, boosting care access in Tennessee by being able to treat more patients grappling with serious illnesses.
Here's Why Select Medical (SEM) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Select Medical (SEM) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Select Medical (SEM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Select Medical (SEM) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook
by Zacks Equity Research
SEM reiterates that earnings for 2025 are likely to be between $1.09 and $1.19 per share.
Select Medical (SEM) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -2.22% and 0.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 22.88% and 7.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Surges 10.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Humana (HUM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
EHC Gains on Sustained Revenue Growth, Expansion Plans
by Zacks Equity Research
Encompass Health benefits from strong patient volumes, continued expansion endeavors across the United States and a robust 2025 business outlook.
Select Medical Q4 Earnings Miss Estimates, Stock Down 7.2%
by Zacks Equity Research
SEM expects revenues to be between $5.4 billion and $5.6 billion, the mid-point of which implies 5.8% growth from the 2024 figure of $5.2 billion.
Select Medical (SEM) Lags Q4 Earnings Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -5.26% and 1.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
SEM Plunges 48.2% in 6 Months: Should You Buy, Hold or Sell the Stock?
by Zacks Equity Research
Rising expenses and high leverage are impacting Select Medical's prospects.
Why Now is the Time to Buy Tenet Stock After a 15% Drop
by Kaibalya Pravo Dey
THC's cheaper valuation, combined with strong earnings growth and robust free cash flow, makes it an appealing pick for value investors.
5 Low Price-to-Book Value Stocks to Buy in December
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, SEM, AXS, ZIM and PFE are some such stocks.
All You Need to Know About Select Medical (SEM) Rating Upgrade to Buy
by Zacks Equity Research
Select Medical (SEM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging -38.05% in 4 Weeks, Here's Why the Trend Might Reverse for Select Medical (SEM)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Select Medical (SEM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Teladoc Enhances Virtual Sitter With AI for Improved Care Delivery
by Zacks Equity Research
TDOC's upgraded Virtual Sitter uses AI to prevent patient falls, boost staff efficiency and enhance care delivery, thus addressing major challenges in hospitals and health systems.
Select Medical Distributes Concentra Shares to Shareholders
by Zacks Equity Research
By separating from Concentra, which specializes in occupational health services, SEM can better allocate resources to its primary segments.
Why Select Medical (SEM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.